Ten-Nine Technologies was founded in 2014 with a dream of creating new materials for new economies. Today, Ten-Nine brings to market breakthrough materials for the energy and chemical industries across a broad range of applications, including energy storage. Ten-Nine’s proprietary nano additive, TENIX™, dramatically improves performance in cathodes - the primary driver of battery cost, performance, and greenhouse gas emissions. It’s a simple powder, produced sustainably and domestically, that can be dropped into manufacturing lines for all kinds of batteries from single-use alkaline cells to rechargeable EV packs. Ten-Nine is based in Tulsa, Oklahoma and works with leading industry partners to transform energy storage with TENIX™.
MaxQ is the largest blood packaging solutions company in the US serving over 1,200 healthcare institutions, blood centers, organ procurement organizations, diagnostic labs, specialty pharmacies, and biopharma manufacturers. MaxQ specializes in providing innovative smart shipping containers for preserving the integrity and safety of temperature-sensitive products. With a proven track record in handling and storing critical assets, such as blood products, vaccines, and specialty medications, we're dedicated to redefining cold chain packaging and delivering exceptional value to our clients worldwide.
Wheeler Bio is a pioneering Contract Development and Manufacturing Organization (CDMO) focused on accelerating the discovery-to-development process for biopharmaceutical companies. Through a unique partnering model, we aim to address industry bottlenecks by facilitating smoother transitions between discovery and development phases, empowering innovators to bring novel antibody and antibody-like therapeutics to market with precision, speed, and optimized cost without ever compromising quality. Wheeler Bio specializes in mammalian cell line and process development, GLP Tox material supply, and CGMP clinical supply, leveraging our Portable CMC® platform to streamline the pathway from innovation to clinical trials. Our approach has been purposefully designed to reduce lifecycle challenges, enhance efficiency, and foster lasting collaborations within the biopharma industry.
Register to attend the 2024 OVF Awards Event
